Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

8/9/2005 12:39:55 PM ET

CVS/PHARMACY NOW OFFERING SWISS MEDICA’S PMS ESCAPE® PRODUCT

FOR IMMEDIATE RELEASE

Stock Symbol: OTC BB: SWME

Aug 9, 2005

CVS/PHARMACY NOW OFFERING SWISS MEDICA’S PMS ESCAPE® PRODUCT

TORONTO--(BUSINESS WIRE)--Aug. 9, 2005--Swiss Medica, Inc. (OTCBB: SWME) is pleased to announce that

CVS/pharmacy is now offering the PMS Escape® product nationwide.

“We are excited CVS/pharmacy has become our first U.S. national pharmacy chain to carry PMS Escape®,” said

Wendy Kramer, Swiss Medica’s Vice President. “We believe this will offer millions of women the opportunity to

purchase PMS Escape® – a clinically studied, patented, safe and effective product for the normal mood and

appetite symptoms associated with premenstrual syndrome.”

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a

world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com,

and

Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain

relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by

healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available

throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit

, for ordering details and store locators for the nearest pharmacy.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS

Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce

changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:

www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United

States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

For more information, please contact:

Swiss Medica Inc.

Investor Relations Contact:

David Jones

(866) 485-4243